Gatto F, Campana C, Cocchiara F, Corica G, Albertelli M, Boschetti M, et al. Current perspectives on the impact of clinical disease and biochemical control on comorbidities and quality of life in acromegaly. Rev Endocr Metab Disord. 2019;20:365–81.

CAS  PubMed  Google Scholar 

Esposito D, Ragnarsson O, Johannsson G, Olsson DS. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020;182:523–31.

CAS  PubMed  Google Scholar 

Giustina A, Biermasz N, Casanueva FF, Fleseriu M, Mortini P, Strasburger C, et al. Consensus on criteria for acromegaly diagnosis and remission. Pituitary. 2024;27:7–22.

CAS  PubMed  Google Scholar 

Melmed S, Bronstein MD, Chanson P, Klibanski A, Casanueva FF, Wass JAH, et al. A Consensus Statement on acromegaly therapeutic outcomes. Nat Reviews Endocrinol. 2018;14:552.

Google Scholar 

Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C et al. A Consensus on the diagnosis and treatment of Acromegaly comorbidities: an update. J Clin Endocrinol Metab. 2019.

Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, et al. Multidisciplinary management of acromegaly: a consensus. Rev Endocr Metab Disord. 2020;21:667–78.

PubMed  PubMed Central  Google Scholar 

Fleseriu M, Langlois F, Lim DST, Varlamov EV, Melmed S. Acromegaly: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2022;10:804–26.

CAS  PubMed  Google Scholar 

Antunes X, Ventura N, Camilo GB, Wildemberg LE, Guasti A, Pereira PJM, et al. Predictors of surgical outcome and early criteria of remission in acromegaly. Endocrine. 2018;60:415–22.

CAS  PubMed  Google Scholar 

Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707–16.

CAS  PubMed  Google Scholar 

Colao A, Bronstein MD, Freda P, Gu F, Shen C-C, Gadelha M, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014;99:791–9.

CAS  PubMed  PubMed Central  Google Scholar 

Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014;2:875–84.

CAS  PubMed  Google Scholar 

Gadelha M, Marques NV, Fialho C, Scaf C, Lamback E, Antunes X et al. Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years’ single-center real-world experience. J Clin Endocrinol Metab. 2023;dgad378.

Ruiz S, Gil J, Biagetti B, Venegas E, Cámara R, Garcia-Centeno R, et al. Magnetic resonance imaging as a predictor of therapeutic response to pasireotide in acromegaly. Clin Endocrinol (Oxf). 2023;99:378–85.

CAS  PubMed  Google Scholar 

Urbani C, Dassie F, Zampetti B, Mioni R, Maffei P, Cozzi R et al. Real-life data of Pasireotide LAR in Acromegaly: a long-term follow-up. J Endocrinol Invest. 2024.

Araujo-Castro M, Biagetti B, Menedez-Torre E, Novoa-Testa I, Cordido F, Pascual-Corrales E et al. Pegvisomant or pasirotide in PRL and GH co-secreting vs GH-secreting Pit-NETs. Endocr Relat Cancer. 2024;ERC-24-0043.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.

PubMed  PubMed Central  Google Scholar 

Cuschieri S. The STROBE guidelines. Saudi J Anaesth. 2019;13:S31–4.

PubMed  PubMed Central  Google Scholar 

DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.

CAS  PubMed  Google Scholar 

R: The R Project for Statistical Computing [Internet]. [cited 2024 Jul 19]. https://www.r-project.org/

Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153–60.

PubMed  PubMed Central  Google Scholar 

Corica G, Pirchio R, Milioto A, Nista F, Arecco A, Mattioli L et al. Pasireotide effects on biochemical control and glycometabolic profile in acromegaly patients switched from combination therapies or unconventional dosages of somatostatin analogs. J Endocrinol Invest. 2023.

Favero V, Zampetti B, Carioni EI, Dalino Ciaramella P, Grossrubatscher E, Dallabonzana D, et al. Efficacy of pasireotide LAR for acromegaly: a prolonged real-world monocentric study. Front Endocrinol (Lausanne). 2024;15:1344728.

PubMed  Google Scholar 

Chiloiro S, Costa D, Lauretta R, Mercuri V, Sbardella E, Samperi I, et al. Partial response to first generation SSA guides the choice and predict the outcome of second line therapy in acromegaly. Endocrine. 2022;78:343–53.

CAS  PubMed  PubMed Central  Google Scholar 

Chiloiro S, Giampietro A, Visconti F, Rossi L, Donfrancesco F, Fleseriu CM, et al. Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. Endocrine. 2021;73:658–66.

CAS  PubMed  PubMed Central  Google Scholar 

Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP, et al. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol. 2021;184:217–29.

CAS  PubMed  Google Scholar 

Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, et al. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. 2016;174:241–50.

CAS  PubMed  Google Scholar 

Pirchio R, Auriemma RS, Vergura A, Pivonello R, Colao A. Long-term pasireotide therapy in acromegaly: extensive real-life experience of a referral center. J Endocrinol Invest. 2024.

Coopmans EC, El-Sayed N, Frystyk J, Magnusson NE, Jørgensen JOL, van der Lely A-J, et al. Soluble Klotho: a possible predictor of quality of life in acromegaly patients. Endocrine. 2020;69:165–74.

CAS  PubMed  PubMed Central  Google Scholar 

Coopmans EC, Schneiders JJ, El-Sayed N, Erler NS, Hofland LJ, van der Lely A-J, et al. T2-signal intensity, SSTR expression, and somatostatin analogs efficacy predict response to pasireotide in acromegaly. Eur J Endocrinol. 2020;182:595–605.

CAS  PubMed  Google Scholar 

Muhammad A, Coopmans EC, Delhanty PJD, Dallenga AHG, Haitsma IK, Janssen JAMJL, et al. Efficacy and safety of switching to Pasireotide in Acromegaly patients controlled with pegvisomant and somatostatin analogues: PAPE extension study. Eur J Endocrinol. 2018;179:269–77.

CAS  PubMed  Google Scholar 

Muhammad A, Van der Janssen LAJ, Neggers J. S. Efficacy and safety of switching to pasireotide LAR alone or in combination with pegvisomant in acromegaly patients controlled with combination treatment of first-generation somatostatin analogues and weekly pegvisomant (PAPE study): a prospective open-label 48 week study, preliminary results 24 weeks. 2017 [cited 2017 Sep 24]; http://www.endocrine-abstracts.org/ea/0049/ea0049GP174.htm

Fleseriu M, Rusch E, Geer EB, ACCESS Study Investigators. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine. 2017;55:247–55.

CAS  PubMed  Google Scholar 

Stelmachowska-Banaś M, Czajka-Oraniec I, Tomasik A, Zgliczyński W. Real-world experience with pasireotide-LAR in resistant acromegaly: a single center 1-year observation. Pituitary. 2022;25:180–90.

PubMed  Google Scholar 

Witek P, Bolanowski M, Szamotulska K, Wojciechowska-Luźniak A, Jawiarczyk-Przybyłowska A, Kałużny M. The Effect of 6 months’ treatment with pasireotide LAR on glucose metabolism in patients with resistant acromegaly in real-world clinical settings. Front Endocrinol (Lausanne). 2021;12:633944.

PubMed  Google Scholar 

Akirov A, Gorshtein A, Dotan I, Khazen NS, Pauker Y, Gershinsky M, et al. Long-term safety and efficacy of long-acting pasireotide in acromegaly. Endocrine. 2021;74:396–403.

CAS  PubMed  Google Scholar 

Masri-Iraqi H, Akirov A, Shimon I. Medical Treatment Landscape for active acromegaly in a Pituitary Center in Israel. Endocr Pract. 2020;26:1298–303.

PubMed  Google Scholar 

Shimon I, Adnan Z, Gorshtein A, Baraf L, Saba Khazen N, Gershinsky M, et al. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study. Endocrine. 2018;62:448–55.

CAS  PubMed  Google Scholar 

Tahara S, Murakami M, Kaneko T, Shimatsu A. Efficacy and safety of long-acting pasireotide in Japanese patients with acromegaly or pituitary gigantism: results from a multicenter, open-label, randomized, phase 2 study. Endocr J. 2017;64:735–47.

CAS  PubMed  Google Scholar 

Gadelha M, Bex M, Colao A, Pedroza García EM, Poiana C, Jimenez-Sanchez M, et al. Evaluation of the efficacy and safety of switching to Pasireotide in patients with acromegaly inadequately controlled with First-Generation somatostatin analogs. Front Endocrinol (Lausanne). 2019;10:931.

PubMed  Google Scholar 

Lasolle H, Ferriere A, Vasiljevic A, Eimer S, Nunes M-L, Tabarin A. Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study. Endocr Connect. 2019;8:1383–94.

CAS  PubMed  PubMed Central  Google Scholar 

Wolf P, Dormoy A, Maione L, Salenave S, Young J, Kamenický P, et al. Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR. Endocr Connect. 2022;11:e220296.

CAS  PubMed  PubMed Central  Google Scholar 

Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing’s disease or acromegaly. Pituitary. 2016;19:536–43.

CAS  PubMed  PubMed Central  Google Scholar 

Jepsen SL, Albrechtsen NJW, Windeløv JA, Galsgaard KD, Hunt JE, Farb TB et al. Antagonizing somatostatin receptor subtype 2 and 5 reduces blood glucose in a gut- and GLP-1R–dependent manner. JCI Insight [Internet]. 2021 [cited